Biotechnology - Pharmaceutical


Current filters:


Popular Filters

226 to 250 of 817 results

BioCity to develop BioHub at Alderley Park post AstraZeneca


BioCity Nottingham, a UK provider of life sciences business incubation services, has been appointed by…


Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx


US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Regeneron acquires rights to two ophthalmology programs from Sanofi


US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…


Acceleron and Shire not to restart ACE-031 program


Privately-held US biotech firm Acceleron Pharma says that Ireland-headquartered Shire (LSE: SHP) has…

Acceleron PharmaACE-031BiotechnologyLicensingPharmaceuticalRare diseasesResearchShire

Pharma and biotech industries headed toward era of reduced profit margins


In the face of reduced profit margins for the pharmaceutical and biotechnology sectors, an effective…

BiotechnologyFinancialMarkets & MarketingPharmaceuticalResearch

FDA advisory votes against AVEO and Astellas' cancer drug tivozanib


US biotech firm AVEO Oncology (Nasdaq: AVEO) saw its shares plunge as much as 57% in late trading yesterday…

Astellas PharmaAVEO OncologyBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

US and European gastroenterologist's views on hepatitis C treatments


Gastroenterologists in the USA and Europe by health care advisory firm Decision Resources agree that…

Anti-viralsBiotechnologyEuropeMarkets & MarketingNorth AmericaPharmaceuticalResearch

Generics take toll on Sanofi's 1st-qtr sales, with net profit down 33.5%


French drug major Sanofi (Euronext: SAN) today (May 2) reported first-quarter 2013 financial results…


US FDA rejects Titan Pharma's Probuphine NDA


California, USA-based Titan Pharmaceuticals (OTCBB: TTNP) has received a Complete Response Letter from…

BiotechnologyBraeburn PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalProbuphineRegulationTitan Pharmaceuticals

Soligenix and Intrexon collaborate on Melioidosis therapy development


US clinical stage biopharma company Soligenix (OTCBB: SNGX) says it will jointly develop a treatment…

Antibiotics and Infectious diseasesBiotechnologyIntrexonLicensingPharmaceuticalResearchSoligenix

Routine cinacalcet for end stage kidney disease not warranted


Cinacalcet, a drug commonly given to patients with end stage kidney disease to help keep phosphorus and…

AmgenBiotechnologycinacalcetNephrology and HepatologyPharmaceuticalResearchSensipar

FDA approves CSL's Kcentra and accepts Octapharma Octaplex BLA for reversal of anticoagulation


The US Food and Drug Administration has approved Kcentra (prothrombin complex concentrate, human) from…

BiotechnologyCardio-vascularCSL BehringCSL LimitedKcentraNorth AmericaOctapharmaOctaplexPharmaceuticalRegulation

GlaxoSmithKline files for umeclidinium monotherapy approval in Europe


UK pharma giant GlaxoSmithKline (LSE: GSK) has submitted a regulatory application in the European Union…

BiotechnologyEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceumeclidinium

Janssen files for European approval of hep C candidate simeprevir


Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ),…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationsimeprevir

Sanofi's Aubagio delayed onset of clinically definite MS in TOPIC study


French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme announced today positive top-line…


OPKO Health to acquire PROLOR Biotech in $480 million stock deal


Continuing on its acquisitive path, US drugmaker OPKO Health (NYSE: OPK) has signed a definitive agreement…

BiotechnologyMergers & AcquisitionsMetabolicsOPKO HealthPharmaceuticalPROLOR Biotech

Orphan diseases' appeal lies in return on investment, says Evaluate


For many years, Big Pharma's model of success has been the blockbuster: drugs that sell more than $1…

BiotechnologyFinancialMarkets & MarketingPharmaceuticalRare diseasesResearch

World's first long-lasting hemophilia therapies will see Biogen move ahead of Pfizer and Baxter


As US biotech company Biogen Idec (Nasdaq: BIIB) prepares to break into the hemophilia market by launching…

BaxterBiogen IdecBiotechnologyMarkets & MarketingPfizerPharmaceutical

226 to 250 of 817 results

Back to top